Revenue from operations at Rs 1,963 Cr, up 17.7% YoY EBITDA margins at 18.4% with EBITDA up 23.2% YoY PAT at 156Cr, up 30.3% YoY Domestic business sales at 888 Cr, up 12.0% YoY International business sales at 1,075 Cr, up 23.0% YoY Emcure Pharmaceuticals
Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine Dimesylate Capsules in strengths
Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended December 31, 2024. Financial Summary (All numbers in INR Mn., except Margins) QUARTERLY CONSOLIDATED FINANCIALS Q3FY25 Q2FY25 Growth (QoQ) Q3FY24 Growth (YoY) Revenue from Operations 11,377 9,666 18% 11,556 -2% EBITDA 2,303 2,033 13% 2,505 -8% EBITDA % 20% 21% 22% PAT 1,176 972 21% 1,257 -6% PAT % 10% 10% 11% Financial and Business Summary for Q3FY25 The Company voluntarily paused
Senores Pharmaceuticals Ltd. has reported revenue of ₹288 Cr during 9MFY25 ending 31st December,2024, reflecting a robust growth of 157%. The exceptional financial performance underscores the company’s strong business strategies and operational excellence. Key Highlights Total Revenue is 288 Cr which is 157% increase PAT after
Strengthens its commitment to advancing cutting edge research in complex drug delivery) The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations. Emcure’s ERC aims to drive breakthrough research
The Central Drugs Standard Control Organisation (CDSCO), India's apex regulatory authority for pharmaceuticals and medical devices, has officially prohibited the import of second-hand or refurbished medical devices. This decisive action aims to safeguard patient health and bolster the domestic medical device industry. Regulatory Framework and Enforcement In
This launch underscores the growing scientific and high-tech cooperation between Russia and India and aims to meet the needs of the increasing amputee population in India, estimated to be around 1 million individuals Motorica, a top-10 global developer and manufacturer of functional limb prostheses, announces the
Mumbai, December 17, 2024 – Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine
Emcure Pharmaceuticals Ltd. announces the launch of a public awareness campaign on stroke prevention with cricket legend, MS Dhoni. Under this initiative, Emcure and Dhoni, through a video urge everyone to be aware about symptoms of stroke and educate at least one person for identification
Current President Suresh Pattathil, Managing Director and General Manager, AbbVie India passes the baton on to Bhushan Akshikar. Bhushan is the Vice President & Managing Director of GSK (GlaxoSmithKline Pharmaceuticals Ltd) India. The Organisation of Pharmaceutical Producers of India (OPPI), which represents the global research-based pharmaceutical companies
